GF Fund Management’s Akero Therapeutics AKRO Stock Holding History

GF Fund Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,721	Closed	-$81.7K	–	647
2025 Q3	$81.7K	Sell	1,721 -66	-4%	-$3.2K	﹤0.01%	351
2025 Q2	$95.4K	Hold	1,787	–	–	﹤0.01%	370
2025 Q1	$72.3K	Buy	1,787 +321	+22%	+$13.6K	﹤0.01%	388
2024 Q4	$40.8K	Buy	+1,466	New	+$44.4K	﹤0.01%	410

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GF Fund Management's AKRO Position: Q4 2025 in Review

GF Fund Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,721 shares — an estimated $81.7K sold.

GF Fund Management first reported a position in AKRO in Q4 2024 and held it in 4 quarters. The position peaked at $95.4K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

GF Fund Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
GF Fund Management sold 1,721 Akero Therapeutics shares in Q4 2025, an estimated $81.7K.
GF Fund Management first reported a position in Akero Therapeutics in Q4 2024 and held it in 4 quarters.
GF Fund Management's Akero Therapeutics position peaked at $95.4K in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.